Dermatology Products Market: By Product Type (Cleanser, Exfoliator, Serum, Face Oil, Sunscreen, Chemical Peel, Toner, Moisturizer, Face Mask, and Eye Cream), By Form (Oil, Gels, Ointments, Lotion, Cream, Wipes, and Powder), By End User (Female Oriented Products, Male Oriented Products, and Kids Oriented Products), By Geography (North America, Europe, Asia Pacific, Latin America, and MEA), and Forecast to 2030

Dermatology Products Market was valued at USD 16,378.2 million in 2023 and is estimated to grow significantly over forecast period. Dermatological is a class of medications concerned with the care or cure of the body's primary barrier- skin, hair and nails. The diseases could include acne, psoriasis, eczema, and atopic dermatitis. The Increasing Prevalence of skin diseases like Atopic Dermatitis, Acne, Psoriasis and Rosacea is expected to drive the growth of the Dermatology Products Market over the forecast period. In addition, improved awareness regarding skin health, more working women, increased funding from private and government for manufacturing pharmaceutical products and increased R&D investments for advancements of Dermatological products. Moreover, the growing ageing population, particularly in developed regions, is fuelling the demand for anti-ageing skincare products and cosmetic dermatology procedures.

Furthermore, an increasing number of mergers, acquisitions, and product launches among the manufacturers and market players to provide skin care to patients are expected to expand the Dermatology Products Market over the forecast period. For instance, on December 22, 2023, Shiseido subsidiary, Shiseido Americas Corporation, adopted a resolution to acquire DDG Skincare Holdings LLC, a company offering dermatologist-led, science-based prestige skincare under Dr. Dennis Gross Skincare. One notable restraint is the high cost associated with advanced dermatological treatments; high out-of-pocket expenses can deter some patients from seeking optimal skincare solutions. New skin and subcutaneous disease cases were identified, most were fungal (34.0%) and bacterial (23.0%) skin diseases. The highest number of new cases and deaths from skin and subcutaneous diseases was in South Asia. Globally, most new cases were in the 0–4-year age group, with skin and subcutaneous disease incidence slightly higher in men than in women.

Recent Developments of the Market:

• In October 2023, Bimzelx was approved by the Food and Drug Administration (FDA). Bimzlex can help treat moderate to severe plaque psoriasis by blocking the function of proteins in the body that cause inflammation. It's available as a subcutaneous (under the skin) injection in a prefilled pen.
• In January 2022, the FDA approved Cibingo (abrocitinib), an oral JAK1 inhibitor, for adults with refractory moderate to severe atopic dermatitis.